Thesis TrackerZiller Funds Management
Companies discussed, last 12 months
1 companies, monthly, latest action on the rightCommentary
18 Aug 2026Ziller Funds ManagementPMEReducedZiller Funds Management reduced their position in Pro Medicus, trimming it modestly as it added to holdings, because the stock has been a strong performer for the fund, though the manager continues to hold the name for the long term and looks for opportunities to add back when suitable. Ziller notes it likes the founder and views the business as compelling, having used the recent "SaaSpocalypse" sell-off as an opportunity to build a position in a company it had long admired despite valuation being the final hurdle. The manager highlights that Pro Medicus renewed all six contracts up for renewal, an unusual 100% retention rate in software, and points to just 11% penetration in US hospitals against a stated long-term target of more than 90%, with management guiding to 30% growth next year, which Ziller regards as a rare and compelling growth rate.
About Ziller Funds Management
Growth Focused, All-CapZiller Funds Management is a Sydney-based boutique equity manager running the Ziller Global Fund, distributed as an ASX-listed active ETF (ASX: ZILR) with Perennial Investment Management acting as responsible entity. The fund concentrates on global equities, holding high-conviction positions in structurally advantaged growth companies (recent top holdings have included NVIDIA, Tesla and Axon Enterprise), and targets an absolute return in excess of its benchmark over the long term. Ziller has built a reputation for paying meaningful periodic distributions to unitholders, including sizeable end-of-financial-year payouts, alongside its growth-oriented equity exposure. The active ETF structure gives retail investors exchange-traded access to Ziller's concentrated global growth strategy alongside the flexibility of on-market trading.
General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.
11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.